NEW YORK (GenomeWeb News) - DiagnoCure said today that Lab21 will sell its colorectal cancer staging test in the UK and Ireland.

Under the exclusive agreement, Lab21 will promote and sell the Previstage GCC Colorectal Cancer Staging Test in the two countries as part of its oncology testing services. DiagnoCure said that it will process the patient samples in its clinical lab in the US.

The company said that around 9,600 people in the UK could benefit from using the test for planning treatment staging each year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.